Artivion (NYSE:AORT) Given New $32.00 Price Target at Needham & Company LLC

Artivion (NYSE:AORT) had its price target dropped by investment analysts at Needham & Company LLC from $34.00 to $32.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 25.79% from the stock’s current price.

Several other brokerages also recently commented on AORT. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer upped their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Price Performance

Shares of Artivion stock opened at $25.44 on Tuesday. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -1,272.00 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The stock has a 50 day moving average price of $29.68 and a 200-day moving average price of $27.83. Artivion has a one year low of $18.38 and a one year high of $32.33.

Artivion (NYSE:AORT) last announced its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Equities analysts expect that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, CEO James P. Mackin sold 42,156 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. This represents a 5.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the completion of the sale, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 77,224 shares of company stock valued at $2,162,330 in the last quarter. 8.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds have recently made changes to their positions in AORT. Creative Planning lifted its stake in shares of Artivion by 182.1% during the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock worth $762,000 after purchasing an additional 18,486 shares during the last quarter. RiverPark Advisors LLC lifted its stake in shares of Artivion by 151.6% during the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock worth $143,000 after purchasing an additional 3,246 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Artivion by 2,481,700.0% during the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock worth $661,000 after purchasing an additional 24,817 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Artivion by 6.6% during the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock worth $280,000 after purchasing an additional 653 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Artivion by 28.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock worth $522,000 after purchasing an additional 4,295 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.